根据市场公开信息及3月31日披露的机构调研信息，知名私募健顺投资近期对3家上市公司进行了调研， 相关名单如下： 1）新宙邦 （上海健顺投资参与公司业绩说明会） 调研纪要：新宙邦2024年实现营业收入78.47亿元，同比增长4.85%，归母净利润9.42亿元，同比下降 6.83%。氟化液产品凭借技术优势，出货量稳步增长，应用场景广泛，预计未来仍将维持较高毛利水 平。海德福项目处于产能爬坡阶段，预计2025年实现亏损减半，新产品销售逐步放量。2024年国际客户 销售额占总体销售额约30%，预计2025年海外销量基本稳定，波兰工厂交付量将大幅增长。美国加征关 税影响有限，俄亥俄项目按计划推进，预计明年年中批量投产。电解液市场竞争激烈，预计持续1-2 年，2024年销量增长超50%，2025年预计增长30%以上。江西石磊经营状况良好，已步入盈利阶段，预 计2025年持续保持盈利，短期计划将产能提升至3万吨以上，今年重点优化现有产能和技术改造。公司 业务整体保持稳定，预计与去年同期相比情况要好。2025年第一季度至第三季度继续计提股权激励费 用，第四季度视业绩目标调整。 2）怡和嘉业 （健顺投资参与公司电话会形式） 调 ...

Investment Rating - The investment rating for the company is "Buy" [4][18]. Core Views - The company has released a stock incentive plan for 2025, aiming to solidify growth certainty with a target of 20% year-on-year growth for 2026 [3]. - The U.S. ventilator market is gradually stabilizing, with a projected recovery in 2025, leading to potential high growth for the company [4]. - The domestic business share is steadily increasing, and there is potential for market share growth overseas, particularly in the U.S. and Europe [4]. Summary by Sections Stock Incentive Plan - The stock incentive plan involves granting a total of 704,000 restricted shares, accounting for 0.79% of the company's total share capital of 89.6 million shares, to 54 individuals including senior management and key technical personnel [3]. Financial Performance and Forecast - The company expects revenue for 2024 to decline by 21% to 884 million yuan, with a net profit forecast of 161 million yuan, a decrease of 46% [4]. - Revenue growth is projected to rebound to 30% in 2025 and 28% in 2026, with net profit growth of 28% and 31% respectively [4][5]. - The earnings per share (EPS) is expected to be 1.80 yuan in 2024, increasing to 2.31 yuan in 2025 and 3.03 yuan in 2026 [5]. Market Position and Strategy - The company is positioned as a leading domestic manufacturer of ventilators, with a strong market share in the U.S. and plans for global expansion [4]. - The international business accounted for 60.55% of revenue in the first three quarters of 2024, indicating a growing reliance on overseas markets [4].

Group 1: Macro Insights - The report outlines a new order concept of "tariff threats + dollar safety zone" as part of the "Mar-a-Lago Agreement" [3] - Tariffs play a dual role as both a means and an end, with inflation and financial market volatility affecting their implementation pace but not their direction [3][4] - The U.S. aims to promote dollar depreciation to revitalize manufacturing through multilateral and unilateral currency agreements [2][3] Group 2: A-Share Market Strategy - The A-share market is expected to enter a phase of consolidation after previous catalysts, with a lack of strong macro policy or economic growth expectations [4][23] - April is highlighted as a critical month for growth performance in the stock market, with a predicted overall A-share profit growth rate of -1.5% for 2024 [5][24] - The report emphasizes the importance of maintaining a balanced investment style, focusing on sectors benefiting from equipment upgrades and low PB stocks [5][25] Group 3: Company Updates - Jiuli Special Materials achieved a revenue of 10.918 billion yuan in 2024, a year-on-year increase of 27.42%, with a net profit of 1.49 billion yuan [12][14] - The company’s overseas revenue accounted for 42.79% of total revenue in 2024, with a significant growth in composite pipe sales [12][14] - Jiuli Special Materials plans to invest in a project to produce 20,000 tons of high-performance pipes for nuclear and oil and gas applications, indicating future capacity growth [12][14] Group 4: Industry Insights - The "deep-sea technology" sector is identified as a significant growth engine, with China's marine economy exceeding 10 trillion yuan in 2024 [15][16] - The report highlights the rapid development of deep-sea equipment manufacturing as a core component of "deep-sea technology," with a focus on domestic production capabilities [17][18] - Investment recommendations include core midstream deep-sea equipment manufacturers and key component suppliers with strong domestic replacement potential [18]

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The pharmaceutical sector showed signs of recovery with a slight outperformance against the Shanghai and Shenzhen 300 Index, with the Shenwan Pharmaceutical Bio Index rising by 0.98% from March 24 to March 28, 2025, ranking first among 31 Shenwan primary industry indices [2][12]. - Year-to-date, the Shenwan Pharmaceutical Bio Index has increased by 3.53%, outperforming the Shanghai and Shenzhen 300 Index by 4.03 percentage points, ranking 12th among the 31 indices [2][14]. - As of March 28, 2025, the valuation of the pharmaceutical sector stands at 26.72 times (TTM overall method, excluding negative values), with a premium of 139.55% compared to the Shanghai and Shenzhen 300 Index [2][15]. Summary by Sections 1. Weekly Market Review - The pharmaceutical sector outperformed the Shanghai and Shenzhen 300 Index, with a weekly increase of 0.98% [2][12]. - The sector's valuation is at 26.72 times, reflecting a significant premium over the broader market [15]. 2. Important Policies and Events - On March 26, 2025, the National Healthcare Security Administration held a meeting to optimize drug procurement policies, releasing a draft proposal that includes six key areas for improvement, such as optimizing procurement varieties and standards, enhancing quality assessment, and increasing transparency [4][21]. 3. Important Company Announcements - Boteng Co., Ltd. reported a revenue of 3.012 billion yuan for 2024, a year-on-year decrease of 17.87%, with a net profit of -288 million yuan, down 207.83% [22]. - Haier Biomedical reported a revenue of 2.283 billion yuan for 2024, a slight increase of 0.13%, with a net profit of 367 million yuan, down 9.71% [22]. 4. Industry Perspectives - The ongoing drug procurement policies have led to significant price reductions for winning bids, impacting company performance and investor confidence. The recent draft proposal aims to adjust the procurement mechanism to prevent low-price bidding and ensure stable supply [5][23][24]. - The adjustments in the procurement rules are expected to restore investor confidence in hospital medication, with potential recovery for quality generic drug companies [5][24].

Investment Rating - The report maintains an "Overweight" rating for the industry [5] Core Views - The recent issuance of the "Special Action Plan to Boost Consumption" by the Central and State Offices is expected to significantly stimulate consumption, leading to a recovery in the consumer healthcare sector [3][5] - The report highlights that the medical service industry's performance is anticipated to improve due to better expectations and technological upgrades, despite facing challenges in 2024 [5] - The report identifies specific companies that are expected to benefit from these trends, including Aier Eye Hospital, Puren Eye Hospital, Tongce Medical, and others, all rated as "Overweight" [5] Summary by Sections Industry Overview - The report emphasizes the potential for a recovery in consumer healthcare driven by government policies aimed at boosting consumption [3][5] Investment Highlights - The report notes that the medical service sector is experiencing a slowdown in revenue growth due to external pressures, but demand remains strong, suggesting a rebound as economic conditions improve [5] - New surgical techniques and the implementation of supportive policies are expected to stabilize and enhance the average transaction value in consumer healthcare [5] - The home medical device market is projected to benefit from policies encouraging aging-friendly transformations and increased investment in healthcare and elderly care [5] Company-Specific Insights - The report lists several companies with "Overweight" ratings, including Aier Eye Hospital (market cap: 134 billion, projected net profit for 2024: 35.96 billion), Puren Eye Hospital, and others, indicating strong growth potential [6] - Companies like Kefu Medical and Meihua Medical are also highlighted as beneficiaries of the favorable policy environment, although they are not yet rated [5][6]

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, focusing on innovation, overseas expansion, thematic investments, and dividend strategies as the main investment themes [2][17]. Core Insights - The pharmaceutical sector experienced a short-term pullback but remains optimistic about the innovation-driven growth trajectory. Key areas of focus include innovative drugs, international market expansion, and supportive policies for innovation [2][17]. - The report highlights the importance of innovative drugs as a new productive force, with significant policy support expected to accelerate their development [17]. - The report emphasizes the potential of companies with strong clinical pipelines and innovative capabilities, particularly in the context of recent supportive policies for innovative drugs [16][17]. Summary by Sections Current Industry Investment Strategy - The pharmaceutical index fell by 2.72% in the week, underperforming the CSI 300 index by 1.97 percentage points. Year-to-date, the sector has risen by 1.11%, outperforming the CSI 300 by 1.75 percentage points [15]. - The current valuation level (PE-TTM) for the pharmaceutical industry is 26.53 times, with a premium of 75.91% relative to the entire A-share market [15]. Key Companies and Their Performance - **Hengrui Medicine**: Recent updates on lung cancer data show promising results, with an overall response rate (ORR) of 73% and median progression-free survival (mPFS) of 11.5 months, indicating strong commercial potential [16]. - **Innovative Drug Policies**: New policies are expected to encourage commercial insurance companies to invest in innovative drug companies and improve pricing standards [16][17]. Thematic Investment Lines - **Innovation and Overseas Expansion**: The report identifies innovative drugs as a key area, with a high success rate in recent insurance negotiations for innovative drugs [17]. - **Dividend Strategy**: With the 10-year government bond yield falling below 2%, dividend-paying assets with stable growth and cash flow are highlighted as defensive and offensive investment options [9][18]. Recommended Investment Combinations - The report lists several recommended stocks, including Hengrui Medicine, Enhua Pharmaceutical, and Yifan Pharmaceutical, among others, indicating a strong buy rating for these companies based on their growth potential and market performance [19][22].

「解码 LP 」系投资界旗下专注 LP 报道公众号，关注各地基金政策，捕捉 LP 最新动态，欢迎关注！ 截至周五下午，本周及上周（2月1日-2月14日）LP动态共44起。 LP 江苏最大母基金，签约4 0 8亿 投资界-解码LP获悉，2月1 2日，江苏省战略性新兴产业母基金2 0 2 5年新年第一会在南京举 行。会议现场，第二批产业专项基金成功签约——共计2 2只，规模4 0 8亿元，涵盖南京、苏 州、无锡、常州、南通等11个设区市和4户省属企业。 回想去年6月，江苏正式启动总规模5 0 0亿元的江苏省战略性新兴产业母基金，助力当地战 略性新兴产业和未来产业发展。仅用时8个月，两批产业专项基金总规模已超9 0 0亿元，一 场全省自上而下的产业竞赛已经打响。 LP 3 0 0亿，江苏成立新国资平台 日前，江苏省国金投资集团有限公司（以下简称为"国金投资集团"）正式登记成立，注册 资本3 0 0亿元人民币。 而稍早前，共计2 2只、规模4 0 8亿元的江苏省战略性新兴产业母基金第二批产业专项基金完 成签约，掀起江苏全省上下联动的产业竞赛。目睹隔壁杭州"六小龙"的崛起，江苏迎头赶 来。 LP 张雪峰又做LP了 日前 ...

「解码 LP 」系投资界旗下专注 LP 报道公众号，关注各地基金政策，捕捉 LP 最新动态，欢迎关注！ 截至周五下午，本周（1月11日-1月17日）LP动态共31起。 LP 上海国资母基金来了 投资界-解码LP获悉，上周，上海国际集团在上海发起设立了目标规模6 0 - 8 0亿元的上海科 创三期基金，进一步引导长期资本、耐心资本投早、投小、投硬科技。以三期基金启动为起 点，上海科创基金管理规模将正式跨越2 0 0亿元里程碑。 在此一天前，规模1 0 0亿元的上海未来产业基金也正式发布了投资策略，该基金已于近期完 成备案，很快将启动子基金遴选工作。可以看到，2 0 2 5年上海国资发力了。 LP 元禾璞华，宣布募资数十亿 元禾璞华产业并购基金已完成首关，首关规模超1 2亿元，预计今年第二季度完成基金终 关，终关规模不低于2 0亿元。此次LP阵容中，基石投资人为苏州元禾控股股份有限公司、 安徽省高新技术产业投资有限公司，华大九天、晶丰明源、安凯微等多家上市公司、金融机 构以及多地政府引导基金同样位列其中。 与此同时，元禾璞华新一期PE基金和新一期VC基金，分别与上海、北京、江苏等多地政府 引导母基金合作设立，同样 ...

以下文章来源于动脉网 ，作者赵泓维 作者 | 赵泓维 来源 | 动脉网 （ID：vcbeat） 医疗设备厂商的日子近来不太好过。 国信证券的一份调研报告显示：2024年上半年全国医疗设备中标总金额仅为520亿元， 同比降幅高达35%。 动脉网 . 动脉网（www.vbdata.cn）聚焦于技术驱动下生命健康领域产业创新和变革的报道与研究。 设备销量放缓。 其中，磁共振、CT、超声、内窥镜、监护设备的形势尤为严峻，以上品类中标金额分别 为65亿、65亿、60亿、45亿和10亿；对应降幅-40%、-40%、-40%、-50% 和-50%，每一类设备的销量都几近腰斩。 2023Q1-2024Q2医疗设备重要品类中标金额情况（单位：亿元；数据来源：国信证 券） 宏观下的萧条给予了每一家企业同等体验。无论国产龙头迈瑞联影，还是跨国巨擘 GPS，这半年间交出的答卷都不尽如人意。 如今凛冬已至，医学设备的转机还有多远？ 设备销量放缓，企业到底承了多少压？ 医疗设备市场急速缩紧背后，一个最为明显的原因是2023年年中开启的医药反腐风暴。 作为此次行动的重灾区，医疗器械相关的违法操作层出不穷。很多医院管理者通过虚报 费用、收受 ...

证券代码：301367 证券简称：怡和嘉业 公告编号：2023-075 关于全资子公司签订募集资金三方监管协议 之补充协议的公告 北京怡和嘉业医疗科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 经中国证券监督管理委员会《关于同意北京怡和嘉业医疗科技股份有限公司首次公 开发行股票注册的批复》(证监许可[2022]1631 号)同意注册，公司首次公开发行人民币 普通股（A 股）16,000,000 股，每股面值人民币 1.00 元，每股发行价格为 119.88 元，募 集资金总额为人民币 191,808.00 万元，扣除相关发行费用（不含税）人民币 17,981.26 万元（不考虑前期已入损益的 320.75 万元）后，实际募集资金净额为人民币 173,826.74 万元。募集资金已于 2022 年 10 月 25 日划至公司指定账户，天健会计师事务所（特殊 普通合伙）于 2022 年 10 月 25 日对发行人募集资金的到位情况进行了审验，并出具《验 资报告》（天健验[2022]1-119 号）。 公司根据有关规定，设立了相关募集资金专项账户， ...